Skip to main content
SpringerLink
Log in

Lipid-independent pleiotropic effects of statins in the management of acute coronary coronary syndromes

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Acute coronary syndromes involve a complex interplay between the vessel wall, inflammatory cells, and the coagulation cascade. Statins possess beneficial effects that are independent of low-density lipoprotein cholesterol lowering and that have favorable effects on inflammation, the endothelium, and the coagulation cascade. There is now accumulating evidence that these lipid-independent pleiotropic effects are clinically relevant in the management of acute coronary syndromes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Law MR, Wald NJ: Risk factor thresholds: their existence under scrutiny. BMJ 2002, 324:1570–1576.

    Article  PubMed  CAS  Google Scholar 

  2. Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267–1278.

    Article  PubMed  CAS  Google Scholar 

  3. Ray KK, Cannon CP: Time to benefit: an emerging concept for assessing the efficacy of statin therapy in cardiovascular disease. Crit Pathways Cardiol 2005, 4:43–45.

    Article  Google Scholar 

  4. Buchwald H, Varco RL, Matts JP, et al.: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990, 323:946–955.

    Article  PubMed  CAS  Google Scholar 

  5. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711–1718.

    Article  PubMed  CAS  Google Scholar 

  6. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504.

    Article  PubMed  CAS  Google Scholar 

  7. Ray KK, Cannon CP, McCabe CH, et al.: Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005, 46:1405–1410.

    Article  PubMed  CAS  Google Scholar 

  8. Thompson PL, Meredith I, Amerena J, et al.: Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am Heart J 2004, 148:e2.

    Article  PubMed  Google Scholar 

  9. Briel M, Schwartz GG, Thompson PL, et al.: Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006, 295:2046–2056.

    Article  PubMed  CAS  Google Scholar 

  10. Chen L, Chester MR, Crook R, Kaski JC: Differential progression of complex culprit stenoses in patients with stable and unstable angina pectoris. J Am Coll Cardiol 1996, 28:597–603.

    Article  PubMed  CAS  Google Scholar 

  11. Rioufol G, Finet G, Ginon I, et al.: Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation 2002, 106:804–808.

    Article  PubMed  CAS  Google Scholar 

  12. Naghavi M, Libby P, Falk E, et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 2003, 108:1664–1672.

    Article  PubMed  Google Scholar 

  13. Naghavi M, Libby P, Falk E, et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 2003, 108:1772–1778.

    Article  PubMed  Google Scholar 

  14. Fox KA, Poole-Wilson PA, Henderson RA, et al.: Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002, 360:743–751.

    Article  PubMed  CAS  Google Scholar 

  15. Ridker PM, Rifai N, Pfeffer MA, et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998, 98:839–844.

    PubMed  CAS  Google Scholar 

  16. Wong B, Lumma WC, Smith AM, et al.: Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. J Leukoc Biol 2001, 69:959–962.

    PubMed  CAS  Google Scholar 

  17. Laufs U, La Fata V, Plutzky J, Liao JK: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129–1135.

    PubMed  CAS  Google Scholar 

  18. Omori H, Nagashima H, Tsurumi Y, et al.: Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol 2002, 54:395–399.

    Article  PubMed  CAS  Google Scholar 

  19. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al.: Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998, 101:2711–2719.

    Article  PubMed  CAS  Google Scholar 

  20. Fichtlscherer S, Rosenberger G, Walter DH, et al.: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000, 102:1000–1006.

    PubMed  CAS  Google Scholar 

  21. Dimmeler S, Aicher A, Vasa M, et al.: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001, 108:391–397.

    PubMed  CAS  Google Scholar 

  22. Walter DH, Rittig K, Bahlmann FH, et al.: Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002, 105:3017–3024.

    Article  PubMed  CAS  Google Scholar 

  23. Vasa M, Fichtlscherer S, Adler K, et al.: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001, 103:2885–2890.

    Article  PubMed  CAS  Google Scholar 

  24. Assmus B, Urbich C, Aicher A, et al.: HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003, 92:1049–1055.

    Article  PubMed  CAS  Google Scholar 

  25. Dichtl W, Dulak J, Frick M, et al.: HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003, 23:58–63.

    Article  PubMed  CAS  Google Scholar 

  26. Seljeflot I, Tonstad S, Hjermann I, Arnesen H: Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease. Atherosclerosis 2002, 162:179–185.

    Article  PubMed  CAS  Google Scholar 

  27. Paleolog EM, Crossman DC, McVey JH, Pearson JD: Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. Blood 1990, 75:688–695.

    PubMed  CAS  Google Scholar 

  28. Nakagomi A, Freedman SB, Geczy CL: Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 2000, 101:1785–1791.

    PubMed  CAS  Google Scholar 

  29. Eto M, Kozai T, Cosentino F, et al.: Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 2002, 105:1756–1759.

    Article  PubMed  CAS  Google Scholar 

  30. Youssef S, Stuve O, Patarroyo JC, et al.: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002, 420:78–84.

    Article  PubMed  CAS  Google Scholar 

  31. Vollmer T, Key L, Durkalski V, et al.: Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004, 363:1607–1608.

    Article  PubMed  CAS  Google Scholar 

  32. Wolozin B, Kellman W, Ruosseau P, et al.: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000, 57:1439–1443.

    Article  PubMed  CAS  Google Scholar 

  33. McCarey DW, McInnes IB, Madhok R, et al.: Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004, 363:2015–2021.

    Article  PubMed  CAS  Google Scholar 

  34. Wenke K, Meiser B, Thiery J, et al.: Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003, 107:93–97.

    Article  PubMed  CAS  Google Scholar 

  35. De Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z Trial. JAMA 2004, 292:1307–1316.

    Article  PubMed  Google Scholar 

  36. Wiviott SD, de Lemos JA, Cannon CP, et al.: A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006, 113:1406–1414.

    Article  PubMed  CAS  Google Scholar 

  37. Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. N Engl J Med 2005, 352:20–28.

    Article  PubMed  CAS  Google Scholar 

  38. Morrow DA, de Lemos JA, Sabatine MS, et al.: Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006, 114:281–288.

    Article  PubMed  CAS  Google Scholar 

  39. Ray KK, Cannon CP, Cairns R, et al.: Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005, 46:1417–1424.

    Article  PubMed  CAS  Google Scholar 

  40. Cannon CP, Steinberg BA, Murphy SA, et al.: Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006, 48:438–445.

    Article  PubMed  CAS  Google Scholar 

  41. Scirica BM, Morrow DA, Cannon CP, et al.: Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006, 47:2326–2331.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Worts Causeway, Cambridge, CB1 8RN, UK

    Kausik K. Ray

Authors
  1. Kausik K. Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher P. Cannon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kausik K. Ray.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ray, K.K., Cannon, C.P. Lipid-independent pleiotropic effects of statins in the management of acute coronary coronary syndromes. Curr Treat Options Cardio Med 9, 46–51 (2007). https://doi.org/10.1007/s11936-007-0050-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-007-0050-1

Keywords

Search

Navigation